Most studies addressing survival patterns focus on 5-years survival data due to difficulties in long-term patients’ follow up. The aim of this study was to explore data on survival making use of the main advantage of SEER (National Cancer Institute Surveillance, Epidemiology, and End Results) program; that is long-term follow up of patients’ records. This enabled reporting 5-years relative survival, 10-years relative survival, and 20-years relative survival for different types of cancers. Survival trends as a function of time and tumor types were also provided.
SEER*Stat version 8.3.4 was used for data acquisition and analysis, where (SEER 18 Regs Nov 2015 Submission) database was used as the data source. Only cases diagnosed between 1973-2012 with malignant behavior, known age, and microscopic confirmation were included. Relative survival was calculated using Ederer II method. Tumors were classified according to ICD-O-3 into either solid malignancies (8000/3-9581/3) or hematological malignancies (9590/3+).
Cancer cases diagnosed between 1973 and 2012 showed a 5-years relative survival of 64.6% (CI: 64.5%-64.6%), a 10-year relative survival of 58.7% (CI: 58.6%-58.7%), and a 20-years relative survival of 51.4% (CI:51.3%-51.5%). All of these percentages were much higher with solid malignancies than hematological ones [Table].Table:
1469P showing relative survival data as a function of time and tumor type
Long-term follow up data were suggestive of 20-years relative survival of 51.4% for all cancers. Data were also suggestive of improved relative survival over time. Unexpectedly, hematological malignancies, despite most of them being thought of as curable ones, appeared to have lower relative survival than solid tumors.
Clinical trial identification
Legal entity responsible for the study
Mohamed Alaa Gouda
All authors have declared no conflicts of interest.